Your browser is no longer supported. Please, upgrade your browser.
BMRN BioMarin Pharmaceutical Inc. daily Stock Chart
BMRN [NASD]
BioMarin Pharmaceutical Inc.
Index- P/E206.66 EPS (ttm)0.61 Insider Own0.60% Shs Outstand179.90M Perf Week-0.57%
Market Cap22.63B Forward P/E88.34 EPS next Y1.43 Insider Trans-15.43% Shs Float179.59M Perf Month17.09%
Income114.00M PEG- EPS next Q-0.10 Inst Own99.00% Short Float5.49% Perf Quarter58.47%
Sales1.81B P/S12.53 EPS this Y69.50% Inst Trans1.39% Short Ratio6.01 Perf Half Y40.72%
Book/sh18.01 P/B7.00 EPS next Y406.03% ROA2.50% Target Price122.50 Perf Year52.39%
Cash/sh4.78 P/C26.36 EPS next 5Y- ROE3.70% 52W Range62.88 - 129.89 Perf YTD49.10%
Dividend- P/FCF- EPS past 5Y32.00% ROI-0.70% 52W High-2.95% Beta1.08
Dividend %- Quick Ratio1.70 Sales past 5Y17.90% Gross Margin78.90% 52W Low100.48% ATR4.11
Employees3001 Current Ratio2.60 Sales Q/Q25.30% Oper. Margin3.20% RSI (14)67.20 Volatility2.53% 3.78%
OptionableYes Debt/Eq0.27 EPS Q/Q238.80% Profit Margin6.30% Rel Volume0.49 Prev Close126.81
ShortableYes LT Debt/Eq0.15 EarningsApr 29 AMC Payout0.00% Avg Volume1.64M Price126.06
Recom1.80 SMA205.34% SMA5017.49% SMA20043.64% Volume803,104 Change-0.59%
Jul-08-20Downgrade Morgan Stanley Overweight → Equal-Weight $125
Jul-06-20Reiterated Citigroup Buy $105 → $148
Jan-28-20Initiated BMO Capital Markets Market Perform
Jan-27-20Initiated BMO Capital Markets Market Perform
Jan-24-20Upgrade RBC Capital Mkts Sector Perform → Outperform $111 → $113
Nov-27-19Upgrade Barclays Equal Weight → Overweight $86 → $98
Nov-12-19Initiated SunTrust Buy $110
Oct-17-19Resumed BofA/Merrill Buy $90
May-23-19Resumed Citigroup Buy
Apr-09-19Resumed Raymond James Outperform
Jan-02-19Downgrade Raymond James Outperform → Mkt Perform
Dec-14-18Initiated Wolfe Research Outperform
Oct-01-18Initiated Cantor Fitzgerald Overweight $126
Aug-07-18Reiterated Stifel Buy $109 → $114
Aug-03-18Reiterated Stifel Buy $102 → $109
May-16-18Initiated Canaccord Genuity Buy $101
Jan-18-18Resumed Credit Suisse Outperform $113
Oct-06-17Resumed Goldman Buy $129
Sep-15-17Initiated RBC Capital Mkts Sector Perform $93
Sep-14-17Initiated Piper Jaffray Overweight $113
Jul-09-20 03:57PM  
09:10AM  
Jul-08-20 03:31PM  
08:45AM  
Jul-07-20 03:14PM  
Jun-30-20 07:41AM  
Jun-29-20 04:16PM  
Jun-25-20 03:26PM  
Jun-24-20 07:30AM  
Jun-23-20 08:30AM  
Jun-22-20 12:05PM  
12:05PM  
Jun-18-20 03:45PM  
09:01AM  
08:34AM  
Jun-17-20 04:05PM  
09:20AM  
04:47AM  
Jun-15-20 11:40AM  
09:00AM  
08:10AM  
08:09AM  
Jun-11-20 05:14PM  
Jun-10-20 06:07PM  
11:03AM  
Jun-03-20 08:30AM  
Jun-01-20 10:35AM  
01:30AM  
May-31-20 04:01PM  
May-29-20 11:40AM  
11:31AM  
May-27-20 03:03PM  
12:55PM  
10:35AM  
May-19-20 04:15PM  
May-13-20 04:38PM  
May-11-20 11:26PM  
07:16AM  
May-08-20 11:23AM  
May-06-20 08:30AM  
May-04-20 03:12PM  
10:43AM  
02:35AM  
May-03-20 04:01PM  
May-01-20 06:26PM  
06:52AM  
Apr-30-20 09:47AM  
06:54AM  
02:31AM  
Apr-29-20 05:45PM  
04:01PM  
Apr-22-20 04:30PM  
Apr-21-20 08:31AM  
Apr-17-20 07:00AM  
Apr-14-20 08:30AM  
Apr-07-20 11:04AM  
Apr-06-20 08:31AM  
Mar-27-20 11:30AM  
Mar-26-20 02:53PM  
Mar-11-20 09:20PM  
07:09PM  
Mar-09-20 03:10PM  
Mar-04-20 07:18AM  
Feb-27-20 10:38AM  
10:06AM  
Feb-26-20 05:35PM  
05:00AM  
Feb-24-20 09:28AM  
08:59AM  
Feb-21-20 07:46AM  
Feb-20-20 04:05PM  
06:49AM  
Feb-19-20 12:31PM  
Feb-18-20 05:22PM  
Feb-12-20 08:30AM  
Feb-11-20 05:54PM  
Feb-04-20 05:29PM  
07:51AM  
Feb-03-20 04:30PM  
11:27AM  
Jan-29-20 08:30AM  
Jan-27-20 09:08AM  
Jan-26-20 09:55AM  
Jan-24-20 03:56PM  
Jan-15-20 10:35AM  
10:02AM  
Jan-14-20 08:33AM  
Jan-13-20 02:30PM  
08:29AM  
Jan-10-20 08:40AM  
Jan-08-20 08:30AM  
07:30AM  
Jan-06-20 11:35AM  
08:30AM  
Jan-04-20 08:03AM  
Jan-03-20 05:43PM  
Jan-02-20 08:31AM  
Dec-25-19 06:14PM  
Dec-24-19 12:00PM  
09:30AM  
BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; and Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder. Its clinical and pre-clinical product pipeline includes valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; vosoritide, a peptide therapeutic that is in Phase III clinical trial for the treatment of achondroplasia, a form of disproportionate short stature in humans; and BMN 307, an AAV5 mediated gene therapy to normalize blood phenylalanine concentration levels in patients with phenylketonuria. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has collaboration and license agreements with Sarepta Therapeutics and Asubio Pharma Co., Ltd.; and a preclinical collaboration and license agreement with DiNAQOR AG for the development of gene therapies to treat rare genetic cardiomyopathies. The company was founded in 1996 and is headquartered in San Rafael, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dere Willard HDirectorJun 26Sale123.614,430547,59213,290Jun 30 02:11 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerJun 19Option Exercise63.1015,000946,50078,402Jun 23 07:24 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerJun 19Sale124.0015,0001,860,00063,402Jun 23 07:24 PM
LAWLIS V BRYANDirectorJun 05Sale107.464,430476,04818,850Jun 09 06:04 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 08Option Exercise21.5120,000430,200318,552May 12 01:51 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 08Sale91.7220,0001,834,400298,552May 12 01:51 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 04Option Exercise21.515,000107,550303,552May 05 07:22 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 04Sale88.005,000440,000298,552May 05 07:22 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 01Option Exercise21.514,00086,040302,552May 05 07:22 PM
Davis George EricEVP, General CounselMay 01Sale89.3812,5041,117,60865,677May 04 09:45 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 01Sale89.384,000357,520298,552May 05 07:22 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 28Option Exercise21.5120,000430,200318,213Apr 29 07:40 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 28Sale97.5820,0001,951,600298,213Apr 29 07:40 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 27Option Exercise21.5120,000430,200318,213Apr 29 07:40 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 27Sale97.7320,0001,954,600298,213Apr 29 07:40 PM
FUCHS HENRY JPresident, Worldwide R&DApr 24Sale95.8820,0001,917,617102,656Apr 28 02:37 PM
FUCHS HENRY JPresident, Worldwide R&DApr 20Sale90.0017,2131,549,170122,656Apr 22 05:15 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 09Option Exercise21.5110,000215,100308,213Apr 13 06:24 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 09Sale79.0610,000790,600298,213Apr 13 06:24 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerApr 08Sale79.982,407192,51263,064Apr 09 07:58 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 07Option Exercise26.491,00026,490298,213Apr 08 08:54 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerApr 01Sale82.001,537126,03465,471Apr 02 08:39 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMar 25Sale78.471,618126,96467,008Mar 26 08:34 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMar 24Sale74.362,041151,76968,626Mar 26 08:34 PM
LAWLIS V BRYANDirectorMar 17Option Exercise21.513,75080,66322,730Mar 18 08:46 PM
LAWLIS V BRYANDirectorMar 17Sale75.393,750282,71318,980Mar 18 08:46 PM
LAWLIS V BRYANDirectorMar 16Sale76.524,610352,75718,980Mar 18 08:46 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 09Option Exercise21.5110,000215,100306,443Mar 11 09:01 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 09Sale89.5210,000895,200296,443Mar 11 09:01 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 03Option Exercise21.5110,000215,100338,530Feb 05 08:38 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 03Sale83.5010,000835,000328,530Feb 05 08:38 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 30Option Exercise21.511,00021,510328,530Feb 03 07:30 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 14Option Exercise21.518,000172,080335,530Jan 16 08:00 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 14Sale87.958,000703,600327,530Jan 16 08:00 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 08Option Exercise21.514,00086,040331,530Jan 09 04:44 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 08Sale84.924,000339,680327,530Jan 09 04:44 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 07Option Exercise21.513,00064,530330,530Jan 09 04:44 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 07Sale84.463,000253,380327,530Jan 09 04:44 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 27Option Exercise21.515,000107,550332,530Dec 30 07:27 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 27Sale86.165,000430,800327,530Dec 30 07:27 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 26Option Exercise21.513,00064,530330,530Dec 30 07:27 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 26Sale86.433,000259,290327,530Dec 30 07:27 PM
LAWLIS V BRYANDirectorDec 17Option Exercise21.513,75080,66327,340Dec 19 08:09 PM
LAWLIS V BRYANDirectorDec 17Sale83.363,750312,60023,590Dec 19 08:09 PM
Davis George EricEVP, General CounselNov 26Sale79.663,190254,11568,709Nov 27 06:47 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 22Option Exercise21.5110,000215,100337,080Nov 26 01:34 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 22Sale77.6010,000776,000327,080Nov 26 01:34 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 25Option Exercise21.515,000107,550332,520Oct 29 07:16 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 25Sale69.555,000347,750327,520Oct 29 07:16 PM
BIENAIME JEAN JACQUESChief Executive OfficerSep 27Option Exercise21.511,00021,510327,520Sep 30 08:16 PM
LAWLIS V BRYANDirectorSep 17Option Exercise21.513,75080,66327,340Sep 18 06:47 PM
LAWLIS V BRYANDirectorSep 17Sale74.473,750279,26323,590Sep 18 06:47 PM
HERON ELAINE JDirectorAug 07Option Exercise63.101,55397,99447,668Aug 08 07:34 PM